1000/1000
Hot
Most Recent
In the last decade, metabolomics has tried to assert its value in the bladder cancer field. Due to the current invasive diagnostic techniques, such as cystoscopy and the continuous monitoring patients must undergo, the introduction of non-invasive urinary biomarkers for monitoring this disease would be advantageous. This section represents a collection of all the metabolic information that various studies have obtained in recent years on bladder cancer, with particular attention to discovering biomarkers in urine for the diagnosis of this disease. In principle, they would complement cystoscopy or, at best, replace it. However, evaluating the different degrees of reproducibility that the experiments have shown in the indication of biomarkers, a synthesis was proposed to obtain a consensus list that is more reliable to become a guideline for clinical practice.
References | Platform | Control Group (CTRL) | Bladder Cancer Patients (BC) | ||||
---|---|---|---|---|---|---|---|
Type | %M a | Age | Type | %M a | Age | ||
Issaq et al., 2008 [21] | LC-MS | Healthy (48) | 44 | 59 (20–86) | MIBC + NMIBC (41) | 88 | 76 (51–93) |
Pasikanti et al., 2010 [22] | GC-TOF | non-BC (51) | 55 | 67 ± 12 | NMIBC (24) | 83 | 61 ± 12 |
Srivastava et al., 2010 [23] | 1H-NMR | Healthy (37), UTI b (31) bladder stone (2) | 41 | 33 ± 15 | NMIBC (33) | 100 | 45 ± 25 |
Kim et al., 2010 [24] | GC-MS | Healthy (8) | 100 | NR c | NMIBC (8) | 100 | 47–78 |
Huang et al., 2011 [25] | LC-MS | Healthy (32) | 56 | 53 (46–67) | NMIBC (27) | 70 | 56 (42–71) |
Putluri et al., 2011 [26] | LC-MS | Healthy (13) | 62 | 53 ± 11 | MIBC + NMIBC (13) | 85 | 61 ± 14 |
LC-MS | Benign patients (16) | 75 | 69 ± 12 | MIBC + NMIBC (28) | 82 | 66 ± 13 | |
LC-MS | Benign patients (11) | NR | 68 ± 14 | MIBC + NMIBC (34) | NR | 71 ± 10 | |
LC-MS | Healthy (11) | 45 | NR | MIBC + NMIBC (8) | 50 | NR | |
Gamagedara et al., 2012 [27] | LC-MS/MS | No-evidence-of-malignancy (NEM) (12) | NR | NR | BC d (11) | NR | NR |
Huang et al., 2013 [28] | LC-MS | Healthy (24) | 62 | 50 (26–65) | MIBC + NMIBC (19) | 74 | 60 (45–74) |
LC-MS | Kidney cancer (25) | 60 | 55 (27–71) | MIBC + NMIBC (19) | 74 | 60 (45–74) | |
Pasikanti et al., 2013 [29] | GC-TOF | non-BC (61) | 59 | 60 ± 13 | NMIBC (38) | 84 | 68 ± 11 |
Wittmann et al., 2014 [30] | LC and CG MS | non-BC (266) | 64 | 64 | MIBC + NMIBC (66) | 85 | 67 |
Jin et al., 2014 [31] | LC-MS | Healthy (69), benign HU e (52) | 64 | 64 ± 9 | MIBC + NMIBC (138) | 81 | 66 ± 13 |
Peng et al., 2014 [32] | LC-QTOFMS | Hernia (68), UTI b or HU (31) | 91 | 62 ± 12 | MIBC + NMIBC (91) | 70 | 68 ± 13 |
Shen et al., 2015 [33] | LC-MS | Healthy (21) | 57 | 54 ± 19 | MIBC + NMIBC (23) | 78 | 65 ± 13 |
Shao et al., 2017 [34] | UPLC-TOF | Hernia (65) | 95 | 65 ± 13 | MIBC + NMIBC (87) | 62 | 68 ± 14 |
Zhou et al., 2017 [35] | GC-MS | Healthy (35) | 66 | 63 ± 8 | MIBC + NMIBC (50) | 70 | 63 ± 12 |
Mpanga et al., 2018 [36] | LC-MS | Healthy (40) | 55 | 60 (53–81) | BC (40) | 50 | 62 (50–87) |
Cheng et al., 2018 [37] | LC-HRMS | Healthy (78) | 78 | 59 ± 11 | NMIBC (54) | 78 | 62 ± 13 |
Liu et al., 2018 [38] | LC-HRMS | Healthy (203) | 48 | 20–60 | NMIBC (110) | 64 | 64 ± 13 |
Loras et al., 2018 [39] | UPLC-TOF-MS | NMIBC after TURBT (18) | 53 | 67 ± 11 | NMIBC before TURBT (18) | 53 | 67 ± 11 |
Loras et al., 2019 [40] | 1H-NMR | MIBC + NMIBC after TURBT (21) | 67 | 69 ± 10 | MIBC + NMIBC before TURBT (12) | ||
Loras et al., 2019 [41] | 1H-NMR | MIBC + NMIBC after TURBT (17) | 59 | 71 ± 9 | MIBC + NMIBC before TURBT (13) | ||
Jacyna et al., 2019 [42] | 1H-NMR, GC-MS, HPLC-MS | Healthy (24) | 75 | 64 ± 10 | MIBC (24) | 75 | 65 ± 12 |
Wang et al., 2019 [43] | UPLC-MS | Healthy (98) | 59 | 55 (20–91) | NMIBC (53) | 77 | 62 (33–87) |
RCC f (64) | 75 | 53 (14–82) | NMIBC (146) | 77 | 62 (33–87) | ||
Łuczykowski et al., 2021 [44] | SPME-LC-MS | Healthy (24) | 75 | 64 ± 10 | MIBC (24) | 76 | 65 ± 13 |
Pinto et al., 2021 [45] | HS-SPME-GC-MS | Cancer-free (56) | 71 | 52 (45–66) | MIBC + NMIBC (53) | 74 | 69 (43–87) |
Lin et al., 2021 [46] | GC-MS | Hernia (61) | 95 | 65 ± 12 | NMIBC (63) | 71 | 67 ± 13 |
Metabolite | BC/CTRL | References |
---|---|---|
hippuric acid | ↓↓↓↓↓↓↓↓↓↓. a | [23][25][26][27][28][35][39][40][41][42][44] |
citric acid | ↓↓↓↓. | [22][23][29][39][40][41] |
gluconic acid | ↑↑↓↓↓ | [22][29][30][36][44] |
lactic acid | ↑↑↑↑? | [29][30][35][40][42] |
taurine | ↑↑↑. | [23][27][28][40][41] |
uridine | ↑↑↑↓? | [22][24][29][32][42] |
valine | ↑↑↑. | [26][22][30][40][41] |
phenylacetylglutamine | ↑↓↓↓ | [25][28][39][42] |
succinate | ↑↓↓? | [30][31][35][40] |
tyrosine | ↑↑↑↓ | [26][35][39][39][42] |
carnitine | ↑↑↓↓ | [26][31][39][25] |
ribitol | ↑↓↓↓ | [22][29][35][46] |
creatine | ↑↓↓? | [26][30][39][41] |
p-cresol | ↑↑↓ | [29][35][45] |
acetyl-carnitine | ↑↑↓ | [25][39][30] |
5-hydroxyindoleacetic acid | ↑↓↓ | [32][39][42] |
fructose | ↑↓↓ | [22][30][46] |
glutamine | ↑. | [40][41][42] |
histidine | ↑. | [26][41][42] |
erythritol | ↑↑↑ | [29][42] [46] |